Athira Pharma (NASDAQ: ATHA)
Athira Pharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Athira Pharma Company Info
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.
News & Analysis
Athira (ATHA) Q2 Loss Narrows 74%
Why Athira Pharma Stock Imploded Today
Its mid-stage clinical trial failed to help patients with Alzheimer's.
Why Shares of Athira Pharma Are Climbing Today
The clinical trial for its Alzheimer's drug is one step closer to completion.
Why Athira Pharma Crashed Today
There was a big shakeup in the biotech's C-suite.
Why Athira Pharma Stock Dropped Today
The clinical-stage biopharma company announced the pricing of a public stock offering.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.